Pharmacogenomics: questions and concerns

References

• Detienne M. La mythologie des aromates en Grèce. Les Jardins d’Adonis. Paris: Gallimard; 1972. p. 76–113
   Google Scholar
• Mager J, Glaser G, Razin A, et al. Metabolic effects of pyrimidines derived from fava bean glycosides on human erythrocytes deficient in glucose-6-phosphate dehydrogenase. Biochem Biophys Res Commun 1965;20:235–40
   PubMed Web of Science ®Google Scholar
• Dioguardi N, Fiorelli G, Aresu G, et al. Molecular forms of lactic dehydrogenase of fava bean-sensitive subjects. Folia Haematol Int Mag Klin Morphol Blutforsch 1965;83:244–9
   PubMedGoogle Scholar
• Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. Br Med J 2000;320:987–90
   Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 1998;279:1200–5
   Google Scholar
• Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS Pharm Sci 2000;2:E4
   Google Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155–62
   PubMed Web of Science ®Google Scholar
• Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet 2001;29:265–9
   PubMed Web of Science ®Google Scholar
• Renegar G, Rieser P, Manasco P. Pharmacogenetics: the Rx perspective. Expert Rev Mol Diagn 2001;1:255–63
   Google Scholar
• Weinshilboum R. Inheritance and drug response. New Engl J Med 2003;348:529–37
   PubMed Web of Science ®Google Scholar
• Dimasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001;69:297–307
   PubMed Web of Science ®Google Scholar
• Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet 2001;4:204–14
   PubMedGoogle Scholar
• Regalado A. Inventing the pharmacogenomics business. Am J Health Syst Pharm 1999;56:40–50
   PubMed Web of Science ®Google Scholar
• Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001;2:228–31
   PubMed Web of Science ®Google Scholar
• Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002;1:300–8
   PubMed Web of Science ®Google Scholar
• Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm 2000;57:887–98 [quiz 899–901]
   Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. New Engl J Med 2003;348:538–49
   PubMed Web of Science ®Google Scholar
• Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998;63:11–6
   PubMed Web of Science ®Google Scholar
• Bell J. The new genetics in clinical practice. Br Med J 1998;316:618–20
   PubMed Web of Science ®Google Scholar
• Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. New Engl J Med 2001;344:1351–7
   PubMed Web of Science ®Google Scholar
• Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002;40:311–7
   PubMed Web of Science ®Google Scholar
• Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999;56:247–58
   PubMed Web of Science ®Google Scholar
• Kalow W. Medical practice, race, and drug use. Clin Pharmacol Ther 2003;73:132–4
   PubMed Web of Science ®Google Scholar
• Omenn GS. Prospects for pharmacogenetics and ecogenetics in the new millennium. Drug Metab Dispos 2001;29:611–4
   PubMed Web of Science ®Google Scholar
• Morrison PJ. Implications of genetic testing for insurance in the UK. Lancet 1998;352:1647–8
   PubMed Web of Science ®Google Scholar
• Lin Z, Owen AB, Altman RB. Genetics. Genomic research and human subject privacy. Science 2004;305:183
   Google Scholar
• Rothstein MA. Genetic discrimination in employment and the Americans with Disabilities Act. Houst Law Rev 1992;29:23–84
   PubMedGoogle Scholar
• Galton DJ, Ferns GA. Genetic markers to predict polygenic disease: a new problem for social genetics. QJM 1999;92:223–32
   PubMed Web of Science ®Google Scholar
• Hudson KL, Rothenberg KH, Andrews LB, et al. Genetic discrimination and health insurance: an urgent need for reform. Science 1995;270:391–3
   PubMed Web of Science ®Google Scholar
• Rothenberg KH. Genetic information and health insurance: state legislative approaches. J Law Med Ethics 1995;23:312–9
   PubMed Web of Science ®Google Scholar
• McEwen JE, McCarty K, Reilly PR. A survey of medical directors of life insurance companies concerning use of genetic information. Am J Hum Genet 1993;53:33–45
   Google Scholar
• McGleenan T. Legal and policy issues in genetics and insurance. Community Genet 2000;3:45–9
   PubMedGoogle Scholar
• Wolf SM. Beyond ‘genetic discrimination’: toward the broader harm of geneticism. J Law Med Ethics 1995;23:345–53
   PubMed Web of Science ®Google Scholar
• Cox SM, Faucett WA, Chen B, et al. International genetic testing. Genet Med 2003;5:176–82
   PubMed Web of Science ®Google Scholar
• Godard B, Raeburn S, Pembrey M, et al. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet 2003;11(Suppl 2): S123–42
   PubMedGoogle Scholar